Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes
NCT06436742Phase 1Active, not recruiting
- Sponsor
- argenx
- Start
- Sep 2024
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1, randomised, double-blind trial in congenital myasthenic syndrome (CMS) comparing ARGX-119 IV with Placebo IV (2 arms). Primary endpoints: Assessment of adverse events and Change from active-treatment baseline over time for 6-Minute Walk Test distance up to 72 weeks. Started Sep 2024; status: active, not recruiting.
02
Drugs
adimanebart
03
Conditions
congenital myasthenic syndrome (CMS)
Beyond the preview
Go deeper on NCT06436742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06436742.